Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05860465

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer Clinical Trial

Official title:
A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitor Combined With Endocrine Therapy

Clinical Trial Summary

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05860465
Study type Interventional
Source Shanghai Pharmaceuticals Holding Co., Ltd
Contact Shusen Wang
Phone 0086-020-87343811
Email wangshs@sysucc.org.cn
Status Recruiting
Phase Phase 2/Phase 3
Start date September 8, 2023
Completion date August 30, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03781063 - Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT05054751 - GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer Phase 3
Completed NCT03027245 - Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
Not yet recruiting NCT05172518 - Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer Phase 3
Recruiting NCT05430399 - Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer Phase 3
Terminated NCT00634088 - Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Phase 1
Not yet recruiting NCT05403333 - Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05296798 - A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) Phase 3
Completed NCT03437083 - A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
Recruiting NCT05744687 - Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer Phase 2/Phase 3
Active, not recruiting NCT06439771 - A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC Phase 2
Withdrawn NCT05212701 - To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer Phase 2